(Q44264759)

1 December 2017

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia (English)

1 reference

1 December 2017

0 references

0 references

1 reference

Michael H Davidson

1

1 reference

1 December 2017

Thomas McGarry

2

1 reference

1 December 2017

Robert Bettis

3

1 reference

1 December 2017

Lorenzo Melani

4

1 reference

1 December 2017

Leslie J Lipka

5

1 reference

1 December 2017

Alexandre P LeBeaut

6

1 reference

1 December 2017

Ramachandran Suresh

7

1 reference

1 December 2017

Steven Sun

8

1 reference

1 December 2017

Enrico P Veltri

9

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Journal of the American College of Cardiology

1 December 2017

1 reference

1 December 2017

40

1 reference

1 December 2017

12

1 reference

1 December 2017

2125-2134

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

Drug interactions of lipid-altering drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

Defining patient risks from expanded preventive therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis".

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

Comparative tolerability of the HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902610-4

7 January 2021

10.1016/S0735-1097(02)02610-4

Identifiers

DOI

1 reference

1 December 2017

1 reference